The Rise of Predictive Oncology: Artificial Intelligence, Digital Biomarkers, and Personalized Cancer Care

Abstract

Cancer continues to represent one of the most significant global health challenges due to its molecular heterogeneity, dynamic evolution, late-stage diagnosis, and variability in therapeutic response. Conventional oncology approaches have historically relied on population-based treatment paradigms, imaging interpretation, histopathological examination, and isolated molecular biomarkers, which frequently fail to capture the biological complexity underlying tumor initiation, progression, metastasis, and therapeutic resistance. The emergence of predictive oncology has introduced a transformative computational framework that integrates artificial intelligence (AI), digital biomarkers, multi-omics analytics, radiogenomics, and real-time clinical data to enable earlier cancer detection, individualized risk prediction, and precision therapeutic intervention. Predictive oncology combines machine learning, deep learning, transformer-based architectures, and multimodal foundation models to analyze highly heterogeneous datasets generated from radiology, histopathology, genomics, transcriptomics, proteomics, liquid biopsy profiling, wearable devices, and electronic health records. These computational systems are increasingly capable of identifying latent disease signatures, forecasting tumor behavior, predicting treatment response, and optimizing personalized clinical decision-making. Recent advances in AI-driven oncology have demonstrated remarkable improvements in cancer screening, recurrence prediction, survival estimation, digital pathology, immunotherapy response assessment, and adaptive therapeutic planning. Convolutional neural networks and transformer architectures have enabled automated interpretation of medical imaging and histopathological slides with performance approaching expert-level diagnostic accuracy. Simultaneously, multimodal AI systems integrating molecular and clinical datasets have facilitated the development of predictive biomarkers capable of guiding precision medicine strategies across multiple cancer types. Despite these advancements, substantial challenges remain regarding model interpretability, algorithmic bias, data standardization, privacy preservation, regulatory approval, and large-scale clinical implementation. This review comprehensively discusses the rise of predictive oncology and the evolving role of artificial intelligence in early cancer detection, digital biomarker discovery, risk modeling, and precision therapy. The article further highlights emerging computational architectures, multimodal learning systems, explainable AI frameworks, federated oncology networks, and future translational directions that may redefine the next generation of precision oncology.